Hemodiafiltration with endogenous reinfusion for uremic toxin removal in patients undergoing maintenance hemodialysis: a pilot study by Renhua Lu, Yan Fang, Wangshu Wu, Xiaojun Zeng, Tingting Liu, Yue Qian, Yuanyuan Xie, Yijun Zhou, Leyi Gu

“…In terms of safety, the study was meticulous in recording vital signs and the incidence of adverse events throughout its duration.Results The study enrolled 20 patients. …”
Get full text

Atrial fibrillation outcomes in patients from Asia and non-Asia countries: insights from GARFIELD-AF by Karen Pieper, Xian-hong Fang, Kai Sun, Ajay K Kakkar, Saverio Virdone, Shinya Goto, Gloria Kayani, Zhi-Cheng Jing, John Camm, Chun-Yan Cheng, Tian-Yu Lian, Xi-Jie Zhu, Xian-Mei Li

“…The association of geographical region with clinical outcomes (event rates per 100 person-years) were estimated using multivariable Cox models.Results 13 841/52 057 (26.6%) GARFIELD-AF participants were enrolled in Asia. …”
Get full text

Beyond identification of familial hypercholesterolemia: Improving downstream visits and treatments in a large health care system by Harin Lee, Tarun Kadaru, Ruth Schneider, Taylor Triana, Carol Tujardon, Colby Ayers, Mujeeb Basit, Zahid Ahmad, Amit Khera

“…As part of a QI program, random individuals from the registry deemed to possibly have FH were contacted via (1) MyChart message, (2) phone call, (3) letter, and/or (4) InBasket message to their PCP to notify them of the potential FH diagnosis, higher risk of ASCVD events, and offering referral to an FH specialist. …”
Get full text

Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Stud... by Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J. Korman, Yu-Huei Huang, Georgios Kokolakis, Andreas Pinter, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Vassilis Stakias, Ahmed M. Soliman, Simone Rubant, Diamant Thaçi

“…Most frequently reported adverse events (reported in ≥ 5% of patients) in risankizumab-treated patients were COVID-19 infection (8.6%) and nasopharyngitis (5.7%). …”
Get full text

Multiparametric cardiovascular magnetic resonance is associated with outcomes in pediatric heart transplant recipients by Andrew A. Lawson, Kae Watanabe, Lindsay Griffin, Christina Laternser, Michael Markl, Cynthia K. Rigsby, Joshua D. Robinson, Nazia Husain

“…Conclusion: T1 and T2 mapping are associated with early differences in adverse cardiac events in PHTR. These data suggest a role for a multicenter study with a longer follow-up duration.…”
Get full text

Human versus Analogue Insulin for Youth with Type 1 Diabetes in Low-Resource Settings (HumAn-1): protocol for a randomised controlled trial by Éimhín Ansbro, Jing Luo, Chung-Chou H Chang, Kaushik Ramaiya, Bruce L Rollman, Sylvia Kehlenbrink, Sae-Rom Chae, Abigail Foulds, Claire Josey, Christina Lalama, Margaret L Prust, Bedowra Zabeen, Graham Ogle

“…Secondary outcomes include TIR at 12 months and time-in-hypoglycaemia, time-above-range, nocturnal hypoglycaemic events and glycaemic control (ie, haemoglobin A1C (HbA1c)) at 6- and 12-months of follow-up. …”
Get full text

Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights by Juan Li, Xuan Wang, Li Zhou, Jun Guo, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoting Wei, Xinan Sheng, Siming Li, Zhihong Chi, Lili Mao, Bin Lian, Xieqiao Yan, Yan Kong, Caili Li, Xiangyong Gu, Binlei Liu, Hui Tian, Han Hu

“…OH2 was well tolerated without serious adverse events (AEs) or deaths reported. No Grade 3 or higher treatment-related AEs occurred. …”
Get full text

FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial by Laith Alrubaiy, Rachel Cooney, Tariq Iqbal, Mohammed Nabil Quraishi, Susan Manzoor, Christopher Quince, Palak J Trivedi, Andrew D Beggs, Alexandra Vince, Chris Weston, Benjamin Mullish, Sahida Shabir, Nicola Jackson, Anna Rowe, Victoria Homer, Willem van Schaik, Peter Rimmer, Sarah Al-Shakhshir, Arzoo Patel, Derick Gyimah, Miriam Hares, Elena Efstathiou

“…Key secondary outcomes will be to evaluate the impact of FMT on other liver biochemical parameters, PSC risk scores, circulating and imaging markers of liver fibrosis, health-related quality of life measures, IBD activity and the incidence of PSC-related clinical events. Key translational objectives will be to identify mucosal metagenomic, metatranscriptomic, metabolomic and immunological pathways associated with the administration of FMT.Ethics and dissemination The protocol was approved by the South Central—Hampshire B Research Ethics Committee (REC 23/SC/0147). …”
Get full text

Post-extrasystolic variation of ST segment and T wave as a mortality risk predictor after myocardial infarction by Ralf J. Dirschinger, Ralf J. Dirschinger, Alexander Müller, Petra Barthel, Alexander Steger, Michael Dommasch, Axel Bauer, Karl-Ludwig Laugwitz, Georg Schmidt, Daniel Sinnecker, Daniel Sinnecker

“…In a multivariable Cox regression analysis considering left-ventricular ejection fraction, presence of diabetes mellitus, and Global Registry of Acute Coronary Events (GRACE) score, PEST remained significantly associated with mortality (hazard ratio 3.6, 95% CI 1.9–6.9, p < 0.0001). …”
Get full text

Association of blood group types and clinico-pathological features of gynecological cancers (GCs) by Syed Sameer Aga, Muhammad Anwar Khan, Mubarak Al Mansour, Rana Mohammed Hasosah, Lulu Abdullah Alsubaie, Dala Ahmad Alfaify, Malak Badr Alansari, Shahad Obaidallah Almutairi, Saniya Nissar

“…In case of the patient dependent GCs, a significant association between ovarian cancers and recurrence, fallopian tube cancers and adverse events and survival status, vaginal/vulval cancers and TNM stage and mixed GCs and tumor type (carcinoma) was observed (P < 0.05). …”
Get full text

Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma by Leonard D’Amico, Martin Cheever, Steven P Fling, Anna Wright, Kathryn Lurain, Ramya Ramaswami, Irene Ekwede, Thomas S Uldrick, Robert Yarchoan, Judith C Kaiser, Angela Shaulov Kask, Manoj P Menon, Paul Couey, Eli Burnham, Allysson Angeldekao, Byung Ha Lee, Li-Lian Kwok, Chia-Ching Jackie Wang

“…With regard to treatment-emergent adverse events (AEs), all participants had &lt;grade 2 AEs, which included injection site reaction and alanine aminotransferase increase. …”
Get full text

Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors by Michael Hoffmeister, Hermann Brenner, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio, Julien Taieb, David Tougeron, Robyn L Ward, Marco Vitellaro, Thierry André, Pierre Laurent-Puig, Jitendra Jonnagaddala, Francesca Bergamo, Raghav Sundar, Claire Gallois, Michael J Overman, Jakob Nikolas Kather, Lisa Salvatore, Romain Cohen, Rossana Intini, Priya Jayachandran, Miriam Koopman, Javier Ros, Marwan Fakih, Vincenzo Nasca, Giacomo Mazzoli, Jeanine M L Roodhart, Filippo Ghelardi, Elena Elez, Durgesh Wankhede, Marta Ligero, Joseph Zhao, Koen Zwart, Jeroen Derksen, Nicholas Hawkins, Javier Carmona

“…We also observed that females experienced a higher frequency of any-grade immune-related adverse events. Conversely, sex was not prognostic in the independent cohorts of patients with MSI-H CRCs not treated with ICIs. …”
Get full text

Virtual reality-based cognitive–behavioural therapy for the treatment of anxiety in patients with acute myocardial infarction: a randomised clinical trial by Jiajun Weng, Junbo Ge, Jiajia Liu, Juying Qian, Xiao Huang, Yuanyuan Li, Juan Peng, Yan'e Lu, Dong Huang, Pingyuan Yang, Shikun Xu, Lihua Guan, Qibing Wang, Zexin Zhao, Yabin Wei

“…Cybersickness was the main reported adverse event (n=5).Conclusions Our results indicate that VR-CBT can significantly reduce post-AMI anxiety at the acute stage of the illness; the improvement was maintained at the 3-month follow-up.Trial registration number The trial was registered at www.chictr.org.cn with the identifier: ChiCTR2200066435.…”
Get full text

Active Retrograde Extra Backup with a Mother-and-Child Catheter to Facilitate Retrograde Microcatheter Collateral Channel Tracking in Recanalization of Coronary Chronic Total Occlu... by Yong Wang, Xiao-Jiao Zhang, Hong-Wei Zhao, Cheng-Fu Wang, De-Feng Luo, Qing-Kun Meng, Yu Zhu, Jie Tao, Bao-Jun Chen, Yi Li, Ai-Jie Hou, Bo Luan

“…There was no statistically significant difference in major adverse cardiac and cerebrovascular events between the groups during hospitalization p>0.05. …”
Get full text

Molecular-level characterization of supraglacial dissolved and water-extractable organic matter along a hydrological flow path in a Greenland Ice Sheet micro-catchment by E. L. Doting, E. L. Doting, I. T. Stevens, A. M. Kellerman, P. E. Rossel, R. Antony, R. Antony, A. M. McKenna, A. M. McKenna, M. Tranter, L. G. Benning, L. G. Benning, R. G. M. Spencer, J. R. Hawkings, J. R. Hawkings, A. M. Anesio

“…An understanding of weathering crust biogeochemical cycling is especially critical as climatic warming is predicted to lead to an increase in Arctic rainfall, consequently increasing the frequency of weathering crust degradation events, with unknown impacts on the export of supraglacial DOM to downstream ecosystems.…”
Get full text

Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer by Lei Wang, Yafei You, Wenzhuo He, Yu Hou, Lan Li, Li Wang, Chang Jiang, Jiahong Yi, Yaoxiong Xia, Liangping Xia

“…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). However, the efficacy and safety of pralsetinib in real world has rarely been reported.Materials and methodsThis study reviewed the efficacy and safety of pralsetinib in RET fusion-positive NSCLC patients between March 2021 and December 2021. …”
Get full text

Group a Streptococcus remains viable inside fibrin clots and gains access to human plasminogen for subsequent fibrinolysis and dissemination by Henry M. Vu, Thomas E. Moran, Zhong Liang, Yun-Juan Bao, Paulina G. Carles, Jessica C. Keane, Madelyn G. Cerney, Caitlyn N. Dahnke, Ana L. Flores-Mireles, Victoria A. Ploplis, Francis J. Castellino, Shaun W. Lee

“…GAS produces several factors that can initiate the dissolution of these fibrin clots to spread to deeper tissues, but we lack specific understanding of the timing of these events. Our studies demonstrate for the first time that GAS can delay their escape from fibrin clots to gain access to deeper tissues during infection, suggesting a key strategy that GAS utilize to cause more invasive disease.…”
Get full text

مروری بر درمان ترکیبی با دوز ثابت برای پیشگیری ثانویه از حوادث نامطلوب قلبی- عروقی و نتایج اولیه‌ی کارآزمایی بالینی تصادفی شده‌ی PersianPolypill... by معصومه صادقی, حمیدرضا روح افزا, علیرضا ناطقی, دکتر نضال صراف زادگان, مرجان منصوریان, جمشید نجفیان, فاطمه بستان, شروین غفاری حسینی

“…پیامد اولیه، یک نتیجه‌ی بالینی ترکیبی از حوادث نامطلوب قلبی- عروقی (Major adverse cardiovascular events) MACE و پیامد ثانویه، هزینه- اثربخشی درمان با polypill خواهد بود.یافته‌ها: ما 10 مطالعه‌ی تکمیل ‌شده و دو مطالعه‌ی بالینی در حال انجام را شناسایی کردیم که حداقل 10 درصد از شرکت‌کنندگان آن‌ها مبتلا به CVD بودند. …”
Get full text

Ferroptosis-related genes participate in the microglia-induced neuroinflammation of spinal cord injury via NF-κB signaling: evidence from integrated single-cell and spatial transcr... by Siqiao Wang, Li Yang, Zhourui Wu, Chen Li, Shaoke Wang, Zhihui Xiao, Bei Ma, Rongrong Zhu, Liming Cheng

“…Abstract Background Ferroptosis and immune responses are critical pathological events in spinal cord injury (SCI), whereas relative molecular and cellular mechanisms remain unclear. …”
Get full text

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis by Shang‐Gin Wu, Chao‐Chi Ho, James Chih‐Hsin Yang, Shu‐Han Yu, Yen‐Feng Lin, Shu‐Chin Lin, Bin‐Chi Liao, Ching‐Yao Yang, Yen‐Ting Lin, Chong‐Jen Yu, Ya‐Ting Chuang, Wei‐Yu Liao, Kah Yi Yap, Weng Si Kou, Jin‐Yuan Shih

“…Patients with programmed death‐ligand 1 (PD‐L1) expression ≥1% exhibited significantly higher ORR (75 vs. 23.1%; p = .032) and longer PFS (14.0 vs. 6.1 months; p = .022) compared with those with PD‐L1 expression < 1%. Grade ≥ 3 adverse events occurred in 40.9% of patients. Higher peritumour nature killer (NK) cell infiltration and lower peripheral helper T cell counts before treatment were associated with favourable ORR and longer PFS, respectively. …”
Get full text